TABLE 1:
Fold change | ||||||
---|---|---|---|---|---|---|
siRhoC vs. Scr | siRhoC#2 vs. Scr | siRhoA vs. Scr | ||||
Array 1 | Array 2 | Array 1 | Array 2 | |||
ras homologue gene family, member C | RHOC | −7 | −4.6 | −3 | 1.2 | 1.1 |
ras homologue gene family, member A | RHOA | 1 | −1.1 | −1.1 | −5.2 | −4.9 |
Up-regulated | ||||||
NSAID-activated gene 1/growth differentiation factor 15 | NAG-1/GDF15 | 2.5 | 2.5 | 2.6 | −1.1 | −1.3 |
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | p21Cip1/CDKN1A | 3.2 | 3 | 1.1 | 1.1 | 1 |
Growth arrest and DNA damage gene 153 | GADD153/DDIT3 | 4 | 4.6 | 2.8 | −1.4 | −1.3 |
Cyclin-dependent kinase inhibitor 1C (p57, Kip2) | p57Kip2/CDKN1C | 2.1 | 1.7 | 1.2 | 1.3 | 1.6 |
Activating transcription factor 3 | ATF3 | 2.1 | 2.3 | 1.9 | −1.2 | −1.4 |
Cystathionase (cystathionine γ-lyase) | CTH | 2.1 | 2.8 | 1.6 | −1.3 | −1.1 |
Homocysteine-inducible, endoplasmic reticulum stress–inducible, ubiquitin-like domain member 1 | HERPUD1 | 2.3 | 1.9 | 1.9 | −1.1 | 1 |
Growth arrest and DNA damage gene 34 | GADD34 | 3.5 | 3.2 | 1.5 | 1.1 | 1.1 |
Tribbles homologue 3 | TRIB3 | 2 | 1.7 | 1.7 | −1.9 | −1.7 |
Asparagine synthetase | ASNS | 2 | 1.5 | 1.9 | −1.1 | −1.2 |
CCAAT/enhancer-binding protein B | CEBPB | 2.8 | 1.9 | 1.7 | −1.3 | −1.2 |
p8 protein (candidate of metastasis 1) | p8 | 2.8 | 2.3 | 2.6 | −1.4 | −1.6 |
Sequestosome 1 | SQSTM1 | 2.6 | 3 | 3 | 1.1 | 1.3 |
ATPase H+-transporting lysosomal 42-kDa V1 subunit C1 | ATP6V1C1 | 2 | 2 | 1.7 | −1.2 | 1.4 |
UDP-N-acetyl-α-d-galactosamine:polypeptide | GALNT3 | 2.5 | 3 | 1.9 | −1.1 | 1 |
N-Acetylgalactosaminyltransferase 3 (GalNAc-T3) | ||||||
Arginase type II | ARG2 | 4.3 | 3.7 | 1.5 | 1.2 | 1 |
S100 calcium-binding protein P | S100P | 2.6 | 2.8 | 1.5 | −2.8 | −2.6 |
GTP-binding protein overexpressed in skeletal muscle | GEM | 2.1 | 2.8 | 1.9 | −1.1 | −1.1 |
Tripeptidyl peptidase I | TPP1 | 2.5 | 2.5 | 1.6 | 1.1 | 1.1 |
Brain-expressed X-linked-like 1 | BEXL1 | 2.5 | 2 | 1.9 | −1.2 | −1.4 |
HSPB (heat shock 27-kDa)–associated protein 1 | HSPBAP1 | 3 | 2.1 | 1.5 | 1.2 | −1.1 |
Cell cycle progression 1 | CCPG1 | 2 | 2.1 | 1.5 | 1.3 | 1.1 |
Syntaxin 3 | STX3 | 2.1 | 1.6 | 2.1 | 1.1 | −1.1 |
Neutrophil cytosolic factor 2 (65 kDa) | NCF2 | 4 | 7 | 4 | −2 | −1.4 |
Metallothionein 1F (functional) | MT1F | 1.9 | 2.5 | 2 | −1.4 | −1.4 |
Metallothionein 1X | MT1X | 1.9 | 3.5 | 1.9 | −1.3 | 1.3 |
DnaJ (Hsp40) homologue subfamily C, member 12 | DNAJC12 | 1.9 | 2.1 | 1.7 | 1.1 | 1 |
Down-regulated | ||||||
Secreted protein, acidic, cysteine-rich (osteonectin) | SPARC | −3 | −5.7 | −2.1 | 2.3 | 2.3 |
Parathyroid hormone–like hormone | PTHLH | −1.9 | −1.6 | −2 | 1.3 | 1.3 |
Interleukin 1 β | IL1B | −4.3 | −2.3 | −2.3 | −1.1 | −1.1 |
Angiopoietin-like 4 | ANGPTL4 | −2.5 | −4.3 | −2.8 | 1.1 | 1.1 |
Chromosome 1 open reading frame 165 | C1orf165 | −3 | −2.1 | −2.3 | 1.1 | −1.1 |
Plasminogen activator tissue | PLAT | −2.5 | −2 | −1.9 | 1 | −1.1 |
COBL-like 1 | COBLL1 | −2.3 | −2 | −1.9 | −1.9 | −1.2 |
Very low density lipoprotein receptor | VLDLR | −2.3 | −2.1 | −2 | 1.1 | −1.1 |
Opsin 3 (encephalopsin, panopsin) | OPN3 | −2.3 | −2 | −1.6 | 1 | −1.2 |
Retinol-binding protein 4 plasma | RBP4 | −2.3 | −2.8 | −1.9 | 1.1 | −1.1 |
Urotensin 2 | UTS2 | −2 | −3.2 | −1.7 | 1.9 | 1.2 |
Solute carrier family 12 (sodium/potassium/chloride transporters), member 2 | SLC12A2 | −2.1 | −2.8 | −2.1 | 1 | 1 |
Phosphofructokinase, platelet | PFKP | −2.1 | −1.9 | −2.1 | −1.4 | −1.2 |
T-cell receptor β constant 1 | TRBC1 | −2.5 | −2 | −2.1 | −1.5 | −1.1 |
Solute carrier family 2, member 1 | SLC2A1 | −1.5 | −2.1 | −2.5 | 1 | 1 |
Procollagen-proline 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase) α polypeptide II | P4HA2 | −1.6 | −2 | −2 | −1.3 | −1.4 |
NSAID, nonsteroidal anti-inflammatory drug.